Get the Stockscreener App
1.325
5.16%
0.065
Adicet Bio Inc stock is traded at $1.325, with a volume of 327.98K.
It is up +5.16% in the last 24 hours and down -6.69% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$1.26
Open:
$1.26
24h Volume:
327.98K
Relative Volume:
0.91
Market Cap:
$110.01M
Revenue:
$38.70M
Net Income/Loss:
$-142.66M
P/E Ratio:
-0.4871
EPS:
-2.72
Net Cash Flow:
$-98.18M
1W Performance:
-6.03%
1M Performance:
-6.69%
6M Performance:
-8.62%
1Y Performance:
-19.70%
1-Day Range:
$1.25
$1.39
1-Week Range:
$1.20
$1.43
52-Week Range:
$1.05
$3.77
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 - StockTitan
Adicet Bio to Participate in Upcoming Investor Conferences - StockTitan
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
HC Wainwright Reiterates Neutral Rating for Adicet Bio (NASDAQ:ACET) - Defense World
Adicet Bio shares maintain Neutral rating after FDA IND amendment - Investing.com India
Adicet Bio shares maintain Neutral rating after FDA IND amendment By Investing.com - Investing.com Australia
Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC Wainwright - MarketBeat
FDA greenlights Adicet Bio's trial expansion for autoimmune diseases - Investing.com
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome - StockTitan
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Down 11.0% in September - MarketBeat
Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Cubist Systematic Strategies LLC - MarketBeat
Adicet Bio (NASDAQ:ACET) Raised to "Hold" at StockNews.com - MarketBeat
Millennium Management LLC Adjusts Stake in Adicet Bio Inc - GuruFocus.com
Renaissance Technologies LLC Has $1.83 Million Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - MarketBeat
Adicet Bio Inc’s Shares Reel: 36.70% Quarterly Revenue Decline Amid 122.78M Market Cap - The InvestChronicle
Did Adicet Bio Inc (ACET) perform well in the last session? - US Post News
Adicet Bio, Inc.'s (NASDAQ:ACET) large institutional owners must be happy as stock continues to impress, up 11% over the past week - Simply Wall St
Recent Insider Activity Suggests Potential Gains for Adicet Bio Inc (ACET) - Knox Daily
Adicet Bio stock maintains neutral rating amid lupus nephritis trial - Investing.com
Stonepine Capital Management LLC Has $737,000 Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio begins enrolling subjects in Phase I trial of autoimmune disease therapy - Clinical Trials Arena
Stonepine Capital Management LLC Increases Stake in Adicet Bio, Inc. (NASDAQ:ACET) - MarketBeat
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference - Business Wire
Adicet Bio (NASDAQ:ACET) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Adicet Bio (NASDAQ:ACET) Now Covered by Analysts at Guggenheim - MarketBeat
Guggenheim Begins Coverage on Adicet Bio (NASDAQ:ACET) - Defense World
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases - BioSpace
Adicet Bio Launches Phase 1 Trial of ADI-001, Eyes Expansion - TipRanks
Wall Street SWOT: Adicet Bio stock navigates competitive CAR-T waters - Investing.com
Biomarker Data from Oncology Trial for Adicet Bio’s Gamma Delta T-cell Therapy ADI-001 Indicates Potential for Use in Autoimmune Disease - CGTLive™
Analysts’ Weekly Ratings Changes for Adicet Bio (ACET) - Defense World
Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa
Adicet Bio shares hold neutral rating amid positive study data - Investing.com
Adicet Bio (NASDAQ:ACET) Earns Outperform Rating from Wedbush - MarketBeat
Adicet Bio reports promising ADI-001 therapy data - Investing.com
HC Wainwright Reiterates "Neutral" Rating for Adicet Bio (NASDAQ:ACET) - MarketBeat
Adicet Bio reports promising ADI-001 therapy data By Investing.com - Investing.com Australia
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue - BioSpace
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Declines By 10.3% - MarketBeat
Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Acadian Asset Management LLC - MarketBeat
Adicet Bio, Inc. (NASDAQ:ACET) Shares Purchased by Acadian Asset Management LLC - Defense World
Adicet Bio, Inc. (NASDAQ:ACET) Expected to Earn FY2026 Earnings of ($1.11) Per Share - Defense World
Insider Selling: Kauffman Michael, Adicet Bio Inc [ACET] Director divested 5,900 shares - Knox Daily
Adicet Bio, Inc. (NASDAQ:ACET) Forecasted to Post FY2026 Earnings of ($1.11) Per Share - MarketBeat
ACET’s Stock Market Adventure: -19.05% YTD Growth Amidst Volatility - The InvestChronicle
Check Out Adicet Bio Inc (ACET)’s Trade Data Rather Than the Analysts’ Views - SETE News
Adicet Bio (NASDAQ:ACET) Given New $8.00 Price Target at Canaccord Genuity Group - Defense World
Adicet Bio stock target cut by Canaccord Genuity on adjusted expectations - Investing.com
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adicet Bio Inc Stock (ACET) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Jan 25 '24 |
Buy |
2.40 |
3,125,000 |
7,500,000 |
7,526,359 |
| GORDON CARL L | Director |
Jan 25 '24 |
Buy |
2.40 |
3,125,000 |
7,500,000 |
7,526,359 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):